← Back to Search

PD-L1 Inhibitor

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called PF-07225570, alone or with another treatment, in patients with recurring bladder cancer that has not spread to the muscle. The goal is to see if these treatments are safe and effective.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
For participants with high-grade Ta/ T1 disease only, Proportion of participants without high-grade-recurrence at each assessment visit.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Part 2B PF-07225570 and sasanlimabExperimental Treatment2 Interventions
PF-07225570 IVe and sasanlimab SQ Combination Dose Expansion
Group II: Part 2A PF-07225570 monotherapyExperimental Treatment1 Intervention
IVe Single Agent Dose Expansion
Group III: Part 1B PF-07225570 and sasanlimabExperimental Treatment2 Interventions
PF-07225570 IVe and sasanlimab Subcutaneous (SQ) Combination Dose Escalation
Group IV: Part 1A PF-07225570 monotherapyExperimental Treatment1 Intervention
Intravesical (IVe) Single Agent Dose Escalation

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,675 Previous Clinical Trials
28,717,182 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,556 Previous Clinical Trials
25,758,038 Total Patients Enrolled
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top